Mechanisms of action of adjuvants

Frontiers in Immunology

Volumn 4, Issue MAY, 2013, Pages

  Awate, Sunita ^a,b   Babiuk, Lorne A ^c   Mutwiri, George ^a,b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Adjuvants; Antigen presentation; Cell recruitment and activation; Dendritic cells; Inflammasomes; Innate immunity; Mechanisms

Indexed keywords

ADJUVANT; ALUMINUM POTASSIUM SULFATE; ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE; CRYOPYRIN; CYTOKINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; EOTAXIN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLAMMASOME; INFLUENZA VACCINE; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 4; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN PROTEIN; POLY [DI (SODIUM CARBOXYL ATO ETHYL PHENOXY) PHOSPHAZENE; RETINOIC ACID INDUCIBLE PROTEIN I; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; CELL ADHESION; CELL PROLIFERATION; DNA DAMAGE; DRUG MECHANISM; HUMAN; IMMUNOCOMPETENT CELL; INJECTION SITE; INNATE IMMUNITY; MICROARRAY ANALYSIS; NONHUMAN; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE ACTIVATION; TISSUE INJURY; UPREGULATION;

EID: 84883817330     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00114     Document Type: Review

References (114)

1. Awate, S., Wilson, H. L., Lai, K., Babiuk, L. A., and Mutwiri, G. (2012). Activation of adjuvant core response genes by the novel adjuvant PCEP. Mol. Immunol. 51, 292-303.
2. Brewer, J. M., Pollock, K. G. J., Tetley, L., and Russell, D. G. (2004). Vesicle size influences the trafficking, processing, and presentation of antigens in lipid vesicles. J. Immunol. 173, 6143-6150.
3. Bungener, L., Idema, J., ter Veer, W., Huckriede, A., Daemen, T., and Wilschut, J. (2002a). Virosomes in vaccine development: induction of cytotoxic T lymphocyte activity with virosome-encapsulated protein antigens. J. Liposome Res. 12, 155-163.
4. Bungener, L., Serre, K., Bijl, L., Leserman, L., Wilschut, J., Daemen, T., et al. (2002b). Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine 20, 2287-2295.
5. Burrell, L. S., White, J. L., and Hem, S. L. (2000). Stability of aluminium-containing adjuvants during aging at room temperature. Vaccine 18, 2188-2192.
6. Calabro, S., Tortoli, M., Baudner, B.C., Pacitto, A., Cortese, M., O'Hagan, D. T., et al. (2011). Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 29, 1812-1823.
7. Casella, C., and Mitchell, T. (2008). Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell. Mol. Life Sci. 65, 3231-3240.
8. Chamaillard, M., Hashimoto, M., Horie, Y., Masumoto, J., Qiu, S., Saab, L., et al. (2003). An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat. Immunol. 4, 702-707.
9. Choi, J.P., Kim, Y.S., Kim, O.Y., Kim, Y.M., Jeon, S.G., Roh, T.Y., et al. (2012). TNF-alpha is a key mediator in the development of Th2 cell response to inhaled allergens induced by a viral PAMP double-stranded RNA. Allergy 67, 1138-1148.
10. Copland, M. J., Baird, M. A., Rades, T., McKenzie, J. L., Becker, B., Reck, F., et al. (2003). Liposomal delivery of antigen to human dendritic cells. Vaccine 21, 883-890.
11. Cox, J. C., and Coulter, A. R. (1997). Adjuvants-a classification and review of their modes of action. Vaccine 15, 248-256.
12. Coyle, A. J., and Gutierrez-Ramos, J.-C. (2001). The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat. Immunol. 2, 203-209.
13. De Becker, G. V., Moulin, V. R., Pajak, B., Bruck, C., Francotte, M., Thiriart, C., et al. (2000). The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. Int. Immunol. 12, 807-815.
14. De Gregorio, E., Tritto, E., and Rappuoli, R. (2008). Alum adjuvanticity: unraveling a century old mystery. Eur. J. Immunol. 38, 2068-2071.
15. De Smedt, T., Pajak, B., Muraille, E., Lespagnard, L., Heinen, E., De Baetselier, P., et al. (1996). Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J. Exp. Med. 184, 1413-1424.
16. Deres, K., Schild, H., Wiesmuller, K.-H., Jung, G., and Rammensee, H.-G. (1989). In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 342, 561-564.
17. Didierlaurent, A., Ferrero, I., Otten, L. A., Dubois, B., Reinhardt, M., Carlsen, H., et al. (2004). Flagellin promotes myeloid differentiation factor 88-dependent development of Th2-type response. J. Immunol. 172, 6922-6930.
18. Didierlaurent, A. M., Morel, S., Lockman, L., Giannini, S. L., Bisteau, M., Carlsen, H., et al. (2009). AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol. 183, 6186-6197.
19. Dostert, C., Pétrilli, V., Van Bruggen, R., Steele, C., Mossman, B. T., and Tschopp, J. (2008). Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320, 674-677.
20. Dupuis, M., Denis-Mize, K., LaBarbara, A., Peters, W., Charo, I. F., McDonald, D. M., et al. (2001). Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis. Eur. J. Immunol. 31, 2910-2918.
21. Dupuis, M., McDonald, D. M., and Ott, G. (1999). Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice. Vaccine 18, 434-439.
22. Eisenbarth, S. C., Colegio, O. R., O'Connor, W., Sutterwala, F. S., and Flavell, R. A. (2008). Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453, 1122-1126.
23. Ellebedy, A. H., Lupfer, C., Ghoneim, H. E., DeBeauchamp, J., Kanneganti, T.-D., and Webby, R. J. (2011). Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59. Proc. Natl. Acad. Sci. U.S.A. 108, 2927-2932.
24. Embry, C. A., Franchi, L., Nunez, G., and Mitchell, T. C. (2011). Mechanism of impaired NLRP3 inflammasome priming by monophosphoryl lipid A. Sci. Signal. 4, ra28.
25. Flach, T. L., Ng, G., Hari, A., Desrosiers, M. D., Zhang, P., Ward, S. M., et al. (2011). Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat. Med. 17, 479-487.
26. Franchi, L., and Nùñez, G. (2008). The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur. J. Immunol. 38, 2085-2089.
27. Fraser, C. K., Diener, K. R., Brown, M. P., and Hayball, J. D. (2007). Improving vaccines by incorporating immunological coadjuvants. Expert Rev. Vaccines 6, 559-578.
28. Fritz, J. H., Le Bourhis, L., Sellge, G., Magalhaes, J. G., Fsihi, H., Kufer, T. A., et al. (2007). Nod1-mediated innate immune recognition of peptidoglycan contributes to the onset of adaptive immunity. Immunity 26, 445-459.
29. Fujii, S.-I., Shimizu, K., Smith, C., Bonifaz, L., and Steinman, R. M. (2003). Activation of natural killer T cells by a-Galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198, 267-279.
30. Gavin, A. L., Hoebe, K., Duong, B., Ota, T., Martin, C., Beutler, B., et al. (2006). Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 314, 1936-1938.
31. Ghimire, T. R., Benson, R. A., Garside, P., and Brewer, J. M. (2012). Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro. Immunol. Lett. 147, 55-62.
32. Girardin, S. E., Boneca, I. G., Carneiro, L. A. M., Antignac, A., Jéhanno, M., Viala, J., et al. (2003a). Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science 300, 1584-1587.
33. Girardin, S. E., Boneca, I. G., Viala, J. R. M., Chamaillard, M., Labigne, A. S., Thomas, G., et al. (2003b). Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 278, 8869-8872.
34. Glenny, A. T., Pope, C. G., Waddington, H., and Wallace, V. (1926). The antigenic value of toxoid precipitated by potassium-alum. J. Pathol. Bacteriol. 29, 38-45.
35. Glück, R., Mischler, R., Brantschen, S., Just, M., Althaus, B., and Cryz, S. J. (1992). Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J. Clin. Invest. 90, 2491-2495.
36. Goto, N., and Akama, K. (1982). Histopathological studies of reactions in mice injected with aluminum-adsorbed tetanus toxoid. Microbiol. Immunol. 26, 1121-1132.
37. Goto, N., Kato, H., Maeyama, J.-I., Shibano, M., Saito, T., Yamaguchi, J., et al. (1997). Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties. Vaccine 15, 1364-1371.
38. Gram, G. J., Karlsson, I., Agger, E. M., Andersen, P., and Fomsgaard, A. (2009). A novel liposome-based adjuvant CAF01 for induction of CD8(+) cytotoxic T-lymphocytes (CTL) to HIV-1 minimal CTL peptides in HLA-A*0201 transgenic mice. PLoS ONE 4:e6950. doi:10.1371/journal.pone.0006950
39. Grun, J. L., and Maurer, P. H. (1989). Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. Cell. Immunol. 121, 134-145.
40. Guéry, J. C., Ria, F., and Adorini, L. (1996). Dendritic cells but not B cells present antigenic complexes to class II-restricted T cells after administration of protein in adjuvant. J. Exp. Med. 183, 751-757.
41. Guy, B. (2007). The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol. 5, 505-517.
42. Henriksen-Lacey, M., Bramwell, V. W., Christensen, D., Agger, E.-M., Andersen, P., and Perrie, Y. (2010). Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. J. Control Release. 142, 180-186.
43. Herbert, W. J. (1968). The mode of action of mineral-oil emulsion adjuvants on antibody production in mice. Immunology 14, 301-318.
44. Hoebe, K., Janssen, E., and Beutler, B. (2004). The interface between innate and adaptive immunity. Nat. Immunol. 5, 971-974.
45. Hornung, V., Bauernfeind, F., Halle, A., Samstad, E. O., Kono, H., Rock, K. L., et al. (2008). Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 9, 847-856.
46. Hsu, L.-C., Ali, S. R., McGillivray, S., Tseng, P.-H., Mariathasan, S., Humke, E. W., et al. (2008). A NOD2-NALP1 complex mediates caspase-1-dependent IL-1ß secretion in response to Bacillus anthracis infection and muramyl dipeptide. Proc. Natl. Acad. Sci. U.S.A. 105, 7803-7808.
47. Hutchison, S., Benson, R. A., Gibson, V. B., Pollock, A. H., Garside, P., and Brewer, J. M. (2012). Antigen depot is not required for alum adjuvanticity. FASEB J. 26, 1272-1279.
48. Iyer, S., HogenEsch, H., and Hem, S. L. (2003). Relationship between the degree of antigen adsorption to aluminum hydroxide adjuvant in interstitial fluid and antibody production. Vaccine 21, 1219-1223.
49. Janeway, C. A. (1989). Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54, 1-13.
50. Jordan, M. B., Mills, D. M., Kappler, J., Marrack, P., and Cambier, J. C. (2004). Promotion of B cell immune responses via an alum-induced myeloid cell population. Science 304, 1808-1810.
51. Kerkmann, M., Rothenfusser, S., Hornung, V., Towarowski, A., Wagner, M., Sarris, A., et al. (2003). Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J. Immunol. 170, 4465-4474.
52. Khoshnejad, M., Young, P. R., Toth, I., and Minchin, R. F. (2007). Modified influenza virosomes: recent advances and potential in gene delivery. Curr. Med. Chem. 14, 3152-3156.
53. Klaschik, S., Tross, D., and Klinman, D. M. (2009). Inductive and suppressive networks regulate TLR9-dependent gene expression in vivo. J. Leukoc. Biol. 85, 788-795.
54. Klaschik, S., Tross, D., Shirota, H., and Klinman, D. M. (2010). Short- and long-term changes in gene expression mediated by the activation of TLR9. Mol. Immunol. 47, 1317-1324.
55. Klinman, D. M., Yi, A. K., Beaucage, S. L., Conover, J., and Krieg, A. M. (1996). CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl. Acad. Sci. U.S.A. 93, 2879-2883.
56. Kobayashi, H., Horner, A. A., Takabayashi, K., Nguyen, M.-D., Huang, E., Cinman, N., et al. (1999). Immunostimulatory DNA prepriming: a novel approach for prolonged Th1-biased immunity. Cell. Immunol. 198, 69-75.
57. Kofoed, E. M., and Vance, R. E. (2011). Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity. Nature 477, 592-595.
58. Kool, M., Pétrilli, V., De Smedt, T., Rolaz, A., Hammad, H., van Nimwegen, M., et al. (2008a). Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J. Immunol. 181, 3755-3759.
59. Kool, M., Soullié, T., van Nimwegen, M., Willart, M. A. M., Muskens, F., Jung, S., et al. (2008b). Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J. Exp. Med. 205, 869-882.
60. Korsholm, K. S., Petersen, R. V., Agger, E. M., and Andersen, P. (2010). T-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection. Immunology 129, 75-86.
61. Kreuter, J. (1988). Possibilities of using nanoparticles as carriers for drugs and vaccines. J. Microencapsul. 5, 115-127.
62. Krieg, A. M. (2002). CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20, 709-760.
63. LeibundGut-Landmann, S., Grosz, O., Robinson, M. J., Osorio, F., Slack, E. C., Tsoni, S. V., et al. (2007). Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat. Immunol. 8, 630-638.
64. Li, H., Nookala, S., and Re, F. (2007). Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1ß and IL-18 release. J. Immunol. 178, 5271-5276.
65. Li, H., Willingham, S. B., Ting, J. P.-Y., and Re, F. (2008). Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J. Immunol. 181, 17-21.
66. Lightfield, K. L., Persson, J., Trinidad, N. J., Brubaker, S. W., Kofoed, E. M., Sauer, J.-D., et al. (2011). Differential requirements for NAIP5 in activation of the NLRC4 inflammasome. Infect. Immun. 79, 1606-1614.
67. Luke, J. M., Simon, G. G., Soderholm, J., Errett, J. S., August, J. T., Gale, M., et al. (2011). Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine. J. Virol. 85, 1370-1383.
68. Mannhalter, J. W., Neychev, H. O., Zlabinger, G. J., Ahmad, R., and Eibl, M. M. (1985). Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation. Clin. Exp. Immunol. 61, 143-151.
69. Mariathasan, S., Weiss, D. S., Newton, K., McBride, J., O'Rourke, K., Roose-Girma, M., et al. (2006). Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440, 228-232.
70. Marrack, P., McKee, A. S., and Munks, M. W. (2009). Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 9, 287-293.
71. Martinon, F., Mayor, A., and Tschopp, J. (2009). The inflammasomes: guardians of the body. Annu. Rev. Immunol. 27, 229-265.
72. Matzinger, P. (1994). Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991-1045.
73. McCarron, M., and Reen, D. J. (2009). Activated human neonatal CD8+ T cells are subject to immunomodulation by direct TLR2 or TLR5 stimulation. J. Immunol. 182, 55-62.
74. McKee, A. S., Munks, M. W., MacLeod, M. K. L., Fleenor, C. J., Van Rooijen, N., Kappler, J. W., et al. (2009). Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J. Immunol. 183, 4403-4414.
75. Morefield, G. L., Sokolovska, A., Jiang, D., HogenEsch, H., Robinson, J. P., and Hem, S. L. (2005). Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 23, 1588-1595.
76. Morein, B., and Bengtsson, K. L. V. (1999). Immunomodulation by iscoms, immune stimulating complexes. Methods 19, 94-102.
77. Morel, S., Didierlaurent, A., Bourguignon, P., Delhaye, S., Baras, B., Jacob, V., et al. (2011). Adjuvant system AS03 containing a-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29, 2461-2473.
78. Mosca, F., Tritto, E., Muzzi, A., Monaci, E., Bagnoli, F., Iavarone, C., et al. (2008). Molecular and cellular signatures of human vaccine adjuvants. Proc. Natl. Acad. Sci. U.S.A. 105, 10501-10506.
79. Moyle, P. M., and Toth, I. (2008). Self-adjuvanting lipopeptide vaccines. Curr. Med. Chem. 15, 506-516.
80. Osebold, J. W. (1982). Mechanisms of action by immunologic adjuvants. J. Am. Vet. Med. Assoc. 181, 983-987.
81. Ott, G., Barchfeld, G. L., Chernoff, D., Radhakrishnan, R., van Hoogevest, P., and Van Nest, G. (1995). MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm. Biotechnol. 6, 277-296.
82. Pashine, A., Valiante, N. M., and Ulmer, J. B. (2005). Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 11, 63-68.
83. Petrilli, V., Papin, S., Dostert, C., Mayor, A., Martinon, F., and Tschopp, J. (2007). Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ. 14, 1583-1589.
84. Ramanathan, V. D., Badenoch-Jones, P., and Turk, J. L. (1979). Complement activation by aluminium and zirconium compounds. Immunology 37, 881-888.
85. Ramon, G. (1924). Sur la toxine et sur I'anatoxine diphtheriques. Ann. Inst. Pasteur 38, 1-10.
86. Rimaniol, A.-C. C., Gras, G., Verdier, F. O., Capel, F., Grigoriev, V. B., Porcheray, F., et al. (2004). Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. Vaccine 22, 3127-3135.
87. Rosenkrands, I., Vingsbo-Lundberg, C., Bundgaard, T. J., Lindenström, T., Enouf, V., van der Werf, S., et al. (2011). Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes. Vaccine 29, 6283-6291.
88. Sasaki, S., Tsuji, T., Hamajima, K., Fukushima, J., Ishii, N., Kaneko, T., et al. (1997). Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1. Infect. Immun. 65, 3520-3528.
89. Schijns, V. E. J. C. (2000). Immunological concepts of vaccine adjuvant activity: commentary. Curr. Opin. Immunol. 12, 456-463.
90. Schijns, V. E. J. C., and Lavelle, E. C. (2011). Trends in vaccine adjuvants. Expert Rev. Vaccines 10, 539-550.
91. Schild, H., Deres, K., Wiesmüller, K.-H., Jung, G., and Rammensee, H.-G. (1991). Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T cells. Eur. J. Immunol. 21, 2649-2654.
92. Schroder, K., and Tschopp, J. (2010). The inflammasomes. Cell 140, 821-832.
93. Serre, K., Mohr, E., Toellner, K. M., Cunningham, A. F., Granjeaud, S., Bird, R., et al. (2008). Molecular differences between the divergent responses of ovalbumin-specific CD4 T cells to alum-precipitated ovalbumin compared to ovalbumin expressed by Salmonella. Mol. Immunol. 45, 3558-3566.
94. Seubert, A., Calabro, S., Santini, L., Galli, B., Genovese, A., Valentini, S., et al. (2011). Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc. Natl. Acad. Sci. U.S.A. 108, 11169-11174.
95. Seubert, A., Monaci, E., Pizza, M., O'Hagan, D. T., and Wack, A. (2008). The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J. Immunol. 180, 5402-5412.
96. Shah, J. A., Darrah, P. A., Ambrozak, D. R., Turon, T. N., Mendez, S., Kirman, J., et al. (2003). Dendritic cells are responsible for the capacity of CpG oligodeoxynucleotides to act as an adjuvant for protective vaccine immunity against Leishmania major in mice. J. Exp. Med. 198, 281-291.
97. Shaw, M. H., Reimer, T., Sanchez-Valdepenas, C., Warner, N., Kim, Y.-G., Fresno, M., et al. (2009). T cell-intrinsic role of Nod2 in promoting type 1 immunity to Toxoplasma gondii. Nat. Immunol. 10, 1267-1274.
98. Shi, Y., Evans, J. E., and Rock, K. L. (2003). Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425, 516-521.
99. Singh, M., and O'Hagan, D. T. (2003). Recent advances in veterinary vaccine adjuvants. Int. J. Parasitol. 33, 469-478.
100. Siskind, G. W., and Benacerraf, B. (1969). Cell selection by antigen in the immune response. Adv. Immunol. 10, 1-50.
101. Sokolovska, A., Hem, S. L., and HogenEsch, H. (2007). Activation of dendritic cells and induction of CD4+ T cell differentiation by aluminum-containing adjuvants. Vaccine 25, 4575-4585.
102. Solle, M., Labasi, J., Perregaux, D. G., Stam, E., Petrushova, N., Koller, B. H., et al. (2001). Altered cytokine production in mice lacking P2×7receptors. J. Biol. Chem. 276, 125-132.
103. Stanley, M. A. (2002). Imiquimod and the imidazoquinolines: mechanism of action and therapeutic potential. Clin. Exp. Dermatol. 27, 571-577.
104. Sun, H., Pollock, K. G. J., and Brewer, J. M. (2003). Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro. Vaccine 21, 849-855.
105. Tamura, M., and Sasakawa, S. (1983). Induction of human leukocyte interferon by heat-treated poly I: poly C. Biochem. Biophys. Res. Commun. 110, 851-858.
106. Tanaka, T., Legat, A., Adam, E., Steuve, J., Gatot, J.-S., Vandenbranden, M., et al. (2008). DiC14-amidine cationic liposomes stimulate myeloid dendritic cells through Toll-like receptor 4. Eur. J. Immunol. 38, 1351-1357.
107. van Beelen, A. J., Zelinkova, Z., Taanman-Kueter, E. W., Muller, F. J., Hommes, D. W., Zaat, S. A. J., et al. (2007). Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity 27, 660-669.
108. Wagner, T. L., Ahonen, C. L., Couture, A. M., Gibson, S. J., Miller, R. L., Smith, R. M., et al. (1999). Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell. Immunol. 191, 10-19.
109. Wang, H.-B., and Weller, P. F. (2008). Pivotal advance: eosinophils mediate early alum adjuvant-elicited B cell priming and IgM production. J. Leukoc. Biol. 83, 817-821.
110. Wang, Y., Cella, M., Gilfillan, S., and Colonna, M. (2010). Cutting edge: polyinosinic:polycytidylic acid boosts the generation of memory CD8 T cells through melanoma differentiation-associated protein 5 expressed in stromal cells. J. Immunol. 184, 2751-2755.
111. Werninghaus, K., Babiak, A., Groß, O., Hölscher, C., Dietrich, H., Agger, E. M., et al. (2009). Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterizum tuberculosis vaccination requires FcR?-Syk-Card9-dependent innate immune activation. J. Exp. Med. 206, 89-97.
112. Wu, J. J., Huang, D. B., and Tyring, S. K. (2004). Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses. Antiviral Res. 64, 79-83.
113. Yan, W., Chen, W., and Huang, L. (2007). Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. Mol. Immunol. 44, 3672-3681.
114. Zhao, Y., Yang, J., Shi, J., Gong, Y.-N., Lu, Q., Xu, H., et al. (2011). The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature 477, 596-600.